Pandemic (Avian) Influenza

Sumanth Rajagopal; John Treanor

doi:10.1055/s-2007-976488

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2007; 28(2): 159-170
DOI: 10.1055/s-2007-976488

Pandemic (Avian) Influenza

Sumanth Rajagopal¹ , John Treanor¹

¹Department of Medicine, Infectious Diseases Division, University of Rochester School of Medicine and Dentistry, Rochester, New York

Abstract

ABSTRACT

Pandemics of influenza have been reported since the early sixteenth century. Recent pandemics include the Spanish flu (H1N1) from 1918 to 1920 (resulting in ~50 million deaths worldwide); the Asian flu (H2N2) from 1957 to 1958 (resulting in more than 1 million deaths); the Hong Kong flu (H3N2) from 1968 to 1970 (responsible for approximately 700,000 deaths). Avian influenza viruses have now been identified as a source of novel hemagglutinin (HA) and neuraminidases (NAs) associated with pandemics. Although infections in humans with avian strains are uncommon, several outbreaks of severe influenza with highly virulent H5N1 strains derived from infected poultry were reported in China and other Asian countries since 2003. Large-scale culling operations and intensified surveillance led to eradication of H5N1 infection in poultry in some countries, but H5N1 infection in wild birds and domestic poultry has become endemic in many countries. The potential exists for global pandemics of unprecedented magnitude. In this review, we discuss the epidemiology and genetics of avian influenza viruses, the potential for transmission of disease to humans, clinical features of avian influenza infections in humans, appropriate diagnostic testing, and treatment. We also discuss global efforts for disease prevention via a host of programs, including intensified surveillance, culling of infected birds, education of medical personnel and the public, production of vaccines, and use of specific antiviral agents (e.g., adamantanes and neuraminidase inhibitors).

KEYWORDS

Avian influenza - pandemic influenza - H5N1 influenza A virus - human influenza virus

Full Text

References

REFERENCES

1 World Bank .http://Avian Flu: The Economic Costs: www.worldbank.org/avianflu
2 Nicholson K G, Webster R G, Hay A J. Textbook of Influenza. London, UK; Blackwell Science Ltd 1998
3 Johnson N P, Mueller J. Updating the accounts: global mortality of the 1918-1920 “Spanish” influenza pandemic. Bull Hist Med. 2002; 76 105-115
4 Crosby W. America's Forgotten Pandemic: Influenza of 1918. Cambridge; Cambridge University Press 1989
5 Collins S D, Lehmann J. Trends and epidemics of influenza and pneumonia: 1918-1951. Public Health Rep. 1951; 66 1487-1516
6 Taubenberger J K, Morens D M. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006; 12 15-22
7 Nuzum J W, Pilot I, Stangl F H, Bonar B E. 1918 pandemic influenza and pneumonia in a large civil hospital. IMJ Ill Med J. 1976; 150 612-616
8 Centers for Disease Control and Prevention . Pandemics Death Toll Since 1900: http://www.pandemicflu.gov/general/
9 Taubenberger J K, Reid A H, Krafft A E, Bijwaard K E, Fanning T G. Initial genetic characterization of the 1918 “Spanish” influenza virus. Science. 1997; 275 1793-1796
10 Reid A H, Taubenberger J K, Fanning T G. Evidence of an absence: the genetic origins of the 1918 pandemic influenza virus. Nat Rev Microbiol. 2004; 2 909-914
11 Connor R J, Kawaoka Y, Webster R G, Paulson J C. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. Virology. 1994; 205 17-23
12 Ito T, Couceiro J N, Kelm S et al.. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol. 1998; 72 7367-7373
13 Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis. 2006; 12 881-886
14 Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001; 293 1840-1842
15 Webster R G, Geraci J, Petursson G, Skirnisson K. Conjunctivitis in human beings caused by influenza A virus of seals. N Engl J Med. 1981; 304 911
16 Kurtz J, Manvell R J, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996; 348 901-902
17 Koopmans M, Wilbrink B, Conyn M et al.. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004; 363 587-593
18 Tweed S A, Skowronski D M, David S T et al.. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004; 10 2196-2199
19 Puzelli S, Di Trani L, Fabiani C et al.. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis. 2005; 192 1318-1322
20 Peiris M, Yuen K, Leung C et al.. Human infection with influenza H9N2. Lancet. 1999; 354 916-917
21 Guan Y, Shortridge K F, Krauss S, Webster R G. Molecular characterization of H9N2 influenza viruses: were they the donors of the “internal” genes of H5N1 viruses in Hong Kong?. Proc Natl Acad Sci USA. 1999; 96 9363-9367
22 Guan Y, Shortridge K F, Krauss S et al.. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in Southeastern China. J Virol. 2000; 74 9372-9380
23 Butt K M, Smith G JD, Chen H et al.. Human infection with an avian H9N2 influenza a virus in Hong Kong in 2003. J Clin Microbiol. 2005; 43 5760-5767
24 Subbarao K, Klimov A, Katz J et al.. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998; 279 393-396
25 Shortridge K F, Zhou N N, Guan Y et al.. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology. 1998; 252 331-342
26 Chen H, Smith G J, Zhang S Y et al.. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature. 2005; 436 191-192
27 World Health Organization .Cumulative Number Of Confirmed Human Cases Of Avian Influenza A/H5N1 Reported to WHO: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2006_08_23/en/index.html
28 Zhu Q Y, Qin E D, Wang N et al.. Fatal infection with influenza A (H5N1) virus in China. N Engl J Med. 2006; 354 2731-2732
29 Chan P K. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis. 2002; 34(Suppl 2) S58-S64
30 Bender C, Hall H, Huang J et al.. Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998. Virology. 1999; 254 115-123
31 Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol. 1999; 73 1146-1155
32 Matrosovich M N, Matrosovich T Y, Gray T, Roberts N A, Klenk H. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci USA. 2004; 101 4620-4624
33 Shinya K, Hatta M, Yamada S et al.. Characterization of a human H5N1 influenza A virus isolated in 2003. J Virol. 2005; 79 9926-9932
34 Gambaryan A, Tuzikov A, Pazynina G, Bovin N, Balish A, Klimov A. Evolution of the receptor binding phenotype of influenza A (H5) viruses. Virology. 2006; 344 432-438
35 World Health Organization Global Influenza Program Surveillance Network . Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis. 2005; 11 1515-1521
36 Liu J, Xiao H, Lei F et al.. Highly pathogenic H5N1 influenza virus infection in migratory birds. Science. 2005; 309 1206
37 Cheung C L, Rayner J M, Smith G J et al.. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis. 2006; 193 1626-1629
38 Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec. 2006; 81 249-257
39 The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5 . Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005; 353 1374-1385
40 Keawcharoen J, Oraveerakul K, Kuiken T et al.. Avian influenza H5N1 in tigers and leopards. Emerg Infect Dis. 2004; 10 2189-2191
41 Mounts A W, Kwong H, Izurieta H S et al.. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis. 1999; 180 505-508
42 World Health Organization .Review of Latest Available Evidence on Risks to Human Health through Potential Transmission of Avian Influenza (H5N1) through Water and Sewage: http://www.who.int/water_sanitation_health/emerging/h5n1background.pdf
43 Olsen S J, Ungchusak K, Sovann L et al.. Family clustering of avian influenza A (H5N1). Emerg Infect Dis. 2005; 11 1799-1801
44 Ungchusak K, Auewarakul P, Dowell S F et al.. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005; 352 333-340
45 de Jong M D, Cam B V, Qui P T et al.. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005; 352 686-691
46 Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al.. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis. 2005; 11 201-209
47 To K F, Chan P K, Chan K F et al.. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol. 2001; 63 242-246
48 Govorkova E A, Rehg J E, Krauss S et al.. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol. 2005; 79 2191-2198
49 Cheung C, Poon L, Lau A et al.. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet. 2002; 360 1831-1837
50 Seo S H, Hoffmann E, Webster R G. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res. 2004; 103 107-113
51 Shinya K, Hamm S, Hatta M, Ito H, Ito T, Kawaoka Y. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology. 2004; 320 258-266
52 Hayden F G, Hay A J. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol. 1992; 176 119-130
53 Cass L M, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999; 36(Suppl 1) 1-11
54 Centers for Disease Control and Prevention .Safety and Dose study of Peramavir for Influenza Treatment: http://www.clinicaltrials.gov/ct/show/NCT00297050
55 Leneva I A, Roberts N, Govorkova E A, Goloubeva O G, Webster R G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000; 48 101-115
56 Govorkova E A, Fang H, Tan M, Webster R G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother. 2004; 48 4855-4863
57 Leneva I A, Goloubeva O, Fenton R J, Tisdale M, Webster R G. Efficacy of Zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother. 2001; 45 1216-1224
58 Tran T H, Nguyen T L, Nguyen T D et al.. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004; 350 1179-1188
59 World Health Organization .WHO Rapid Advice Guidelines on Pharmacological Management of Humans Infected with Avian Influenza A (H5N1) Virus: http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html
60 Yen H L, Monto A S, Webster R G, Govorkova E A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis. 2005; 192 665-672
61 Treanor J J, Hayden F G, Vrooman P S et al.. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA. 2000; 283 1016-1024
62 Cooper N J, Sutton A J, Abrams K R, Wailoo A, Turner D, Nicholson K G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003; 326 1235-1240
63 de Jong M D, Thanh T T, Khanh T H et al.. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353 2667-2672
64 Le Q M, Kiso M, Someya K et al.. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005; 437 1108
65 Moscona A. Oseltamivir resistance: disabling our influenza defenses. N Engl J Med. 2005; 353 2633-2636
66 Herlocher M L, Truscon R, Elias S et al.. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis. 2004; 190 1627-1630
67 Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu(R)) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005; 55(Suppl 1) 15-21
68 Fedson D S. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy. 2005; 26 4-29
69 Katz J M, Lim W, Bridges C B et al.. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis. 1999; 180 1763-1770
70 Nicholson K G, Colegate A E, Podda A et al.. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet. 2001; 357 1937-1943
71 Treanor J J, Wilkinson B E, Masseoud F et al.. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine. 2001; 19 1732-1737
72 Treanor J J, Campbell J D, Zangwill K M, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006; 354 1343-1351
73 Bresson J L, Perronne C, Launay O et al.. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006; 367 1657-1664
74 Lin J, Zhang J, Dong X et al.. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006; 368 991-997
75 GSK press release. GSK Reports Significant Advance in H5N1 Pandemic Flu Vaccine Programme: http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=868
76 Stephenson I, Nicholson K G, Colegate A et al.. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine. 2003; 21 1687-1693
77 Belshe R B, Mendelman P M, Treanor J et al.. The efficacy of live attenuated, cold-adapted, trivalent, intranasal Influenzavirus vaccine in children. N Engl J Med. 1998; 338 1405-1412
78 Belshe R B, Gruber W C, Mendelman P M et al.. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000; 136 168-175
79 National Strategy for Pandemic Influenza: http://www.whitehouse.gov/homeland/pandemic-influenza.html
80 Yuen K Y, Chan P K, Peiris M et al.. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 1998; 351 467-471
81 Peiris J, Yu W C, Leung C W et al.. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet. 2004; 363 617-619
82 Tamura D, Miura T, Kikuchi Y. Oseltamivir phosphate in infants under 1 year of age with influenza infection. Pediatr Int. 2005; 47 484

Sumanth RajagopalM.D.

Department of Medicine, Infectious Diseases Division, University of Rochester School of Medicine and Dentistry

601 Elmwood Ave., Rochester, NY 14642

Email: sumanth_rajagopal@urmc.rochester.edu